title: Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.
abstract: OBJECTIVE
  To determine the antileukemic activity of weekly oral aminopterin in patients with refractory acute leukemia; to describe the pharmacodynamic properties of aminopterin; and to contrast the intracellular metabolism of aminopterin and methotrexate by patients' blasts in vitro.
  
  
  METHODS
  Forty-six patients were enrolled in three strata: children with acute lymphoblastic leukemia (ALL), adults with ALL, and patients with acute myeloid leukemia (AML). Aminopterin was given weekly, in two doses of 2 mg/m(2), 12 hours apart. Limited sampling pharmacokinetic analysis was done during the first week of therapy. Accumulation of [(3)H]aminopterin and [(3)H]methotrexate by leukemic blasts was studied in vitro.
  
  
  RESULTS
  Six of 22 children with ALL (27%; 95% confidence interval, 8-47%) had clinically significant responses. None of those with AML and only two of 11 adults with ALL had responses meeting protocol definitions, although peripheral blast counts tended to decrease with therapy in all groups. Mucosal toxicity was minimal, even with limited use of leucovorin rescue. Complete bioavailability of aminopterin was confirmed, with a mean area under the curve of 0.52 +/- 0.03 micromol hour/L after oral dosing. No relationship between aminopterin pharmacokinetics and response was seen. In vitro, aminopterin showed more consistent metabolism by leukemic blasts to polyglutamates than methotrexate. Lineage-specific differences in the pattern of intracellular antifolylpolyglutamates were observed.
  
  
  CONCLUSIONS
  Weekly oral aminopterin has significant activity among children with refractory ALL. With greater cellular accumulation and metabolism, more reliable bioavailability than methotrexate, and tolerable toxicity at this dose and schedule, aminopterin deserves further study as a potent alternative to methotrexate.
authors.affiliation: Department of Pediatric Oncology, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA. colepd@umdnj.edu
authors.forename: Peter D
authors.initials: PD
authors.lastname: Cole
authors.forename: Richard A
authors.initials: RA
authors.lastname: Drachtman
authors.forename: Angela K
authors.initials: AK
authors.lastname: Smith
authors.forename: Sarah
authors.initials: S
authors.lastname: Cate
authors.forename: Richard A
authors.initials: RA
authors.lastname: Larson
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Hawkins
authors.forename: John
authors.initials: J
authors.lastname: Holcenberg
authors.forename: Kara
authors.initials: K
authors.lastname: Kelly
authors.forename: Barton A
authors.initials: BA
authors.lastname: Kamen
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000630:Aminopterin / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm; D005260:Female; D005493:Folic Acid Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006412:Hematopoietic Stem Cells / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000208:ethnology; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000208:ethnology; D016896:Treatment Outcome
chemical_list: D005493:Folic Acid Antagonists; D000630:Aminopterin